14 December 2022
*A corporate client of Hybridan LLP
** Arranged by most recent first
*** Alphabetically arranged
Dish of the day
Joiners:
No joiners today.
Leavers:
No leavers today.
What’s cooking in the IPO kitchen?**
Celsius Resources Ltd (ASX:CLA) intends to join AIM. Currently ASX listed, Celsius is a natural resources exploration and development company principally seeking to explore and develop potential world-class copper-gold assets in the Philippines and a cobalt asset in Namibia. Amount planning to raise and anticipated market cap TBC. Expected late December 2022.
Smarttech247 Group intends to join AIM. The company is a provider of AI enhanced cybersecurity services providing automated managed detection and response and has raised £3.67m to support its continued expansion into new products and geographies, development of its proprietary technology and for general working capital purposes. Admission is expected to take place on 15 December 2022 under the TIDM S247.
Conviction Life Sciences, a newly established closed-ended investment company managed by Plain English Finance Limited, is seeking to list on Premium Segment of the Main Market of the London Stock Exchange, to invest in a conviction portfolio of life sciences and medical technology businesses, primarily in the UK, Europe and Australasia. The Company will invest in both Publicly Traded and Private companies - c. 70% and c. 20% of the total portfolio value respectively. The Company will target an annualised Total NAV Return of 20% over the long-term. Targeting to raise c.£100m. Date 16 December.
Kistos Holdings intends to join AIM. The Company was incorporated to act as a new holding company for the group companies 0f Kistos PLC (AIM:KIST) (KIST), a holding company with the objective of creating value for its investors through the acquisition and management of companies or businesses in the energy sector. Anticipated Market Cap £327m. Expected 22 Dec 2022.
Banquet Buffet***
Afentra plc (AIM:AET) 25.2p £55.5m
The independent oil and gas company provides an update on the Angolan acquisitions. On 28 April 2022, its wholly-owned subsidiary, Afentra (Angola) Ltd, had signed a sale and purchase agreement with Sonangol Pesquisa e Producao S.A. (Sonangol) to purchase non-operating interests in Block 3/05 (20%) and Block 23 (40%), offshore Angola, subject to a number of conditions precedent (CPs) including the receipt of governmental approvals and the extension of the Block 3/05 Production Sharing Agreement (PSA) until at least 31 December 2040. However, PSA extension is now unlikely to be finalised before 31 December 2022 and the Company, together with Sonangol, are working on extending the long stop date in order to facilitate satisfaction of the remaining CPs to enable completion in Q1 2023.
CyanConnode Holdings PLC (AIM:CYAN) 13.375p £32.2m
The company that engages in the design, development and sale of narrowband radio frequency (RF) mesh networks, announces its interim results for the six months ended 30 September 2022 (H1 FY 2023). Revenue is £1.3m (H1 FY 2022: £4.1m), in line with the Board's expectations (management forecast that circa 90% of full year revenue will be delivered in H2). Operating loss was £2.4m (H1 FY 2022: loss of £1.2m). Cash and cash equivalents was £1.0m (H1 FY 2022: £1.7m). The company expects to meet market revenue forecasts for the full financial year ended 31 March 2023.
Fulcrum Utility Services Ltd (AIM:FCRM) 1.5p £6.0m
The independent provider of essential utility services including multi-utility connections and renewable energy infrastructure, announces its interim results for the six-month period ended 30 September 2022. Revenues decreased by 16% to £23.9m (H122: £28.6m). Adjusted EBITDA was £(3.3)m (H122: £1m). Net cash position as at 30 September 2022 was £4.8m (30 September 2021: net debt of £3.3m). The series of multi-utility contracts signed during the period have been under the revised contractual terms, in order to protect the company’s profitability.
GetBusy PLC (AIM:GETB) 62p £30.6m
The provider of productivity software for professional and financial services, provides a trading update on the financial year ended 31 December 2022. Total revenue is expected to grow by 24% to at least £19.1m, around 4% ahead of the previously upgraded market expectations, with recurring revenue expected to grow c.27%. As a result, the Board's ambition to at least double Annual Recurring Revenue (ARR) within five years, as announced in 2021, is firmly on track. Adjusted loss before tax is expected to have narrowed by 20-25% compared to market expectations. Net cash at 30 November 2022 was £2.2m and the Group's £2m debt facility remains entirely undrawn.
Helium One Global Ltd (AIM:HE1, OTCQB:HLOGF) 5.7p £35.5m
The primary helium explorer in Tanzania announces that it has raised gross proceeds of approximately £9.9m at a price of 5.0 pence per share, a discount of c. 26% to the closing price of 6.75 pence per share on 12 December. The fundraise comprised of a Placing to raise approximately £8.8m and a Subscription to raise approximately £1.11m. As announced this morning, the fundraise was upsized from the previous target of £7m minimum due to investor demand. The net proceeds will be used for a targeted single well exploration drilling programme of the Tai prospect in the Rukwa Basin.
LoopUp Group PLC (AIM:LOOP, OTC:LUPGF) 4.25p £7.9m
The cloud platform for premium hybrid communications provides a trading update. In September 2022, the Group announced a revenue sharing and customer transfer agreement with PGi Connect, giving LoopUp the rights to onboard materially all of PGi Connect's conferencing services customers. Following the successful transition of PGi Connect Meetings business and the commercial progress achieved in Cloud Telephony, the Group expects FY22 revenue to be marginally above market expectations at no less than £15.5m (H1 2022: £6.6m). FY22 EBITDA is expected to be marginally below market expectations due to higher PGi Connect transition costs, but not expected to impact FY23 profitability.
Metal Tiger PLC (AIM:MTR, OTC:MRTTF, ASX:MTR) 11.9p $£20.2m
The investor in natural resource opportunities, notes that Cobre Limited (Cobre) has announced that it has entered into a binding Heads of Agreement with Tshukudu Exploration (Pty) Ltd, a subsidiary of ASX-listed Sandfire Resources Limited (Sandfire), to procure Airborne Gravity Gradient data over its Ngami, Kitlanya West and Kitlanya East Copper Projects in Botswana. Metal Tiger currently holds 20.58% of Cobre's issued share capital. Metal Tiger is also interested in 5,706,953 Sandfire shares representing approximately 1.29% of Sandfire’s current issued share capital. Post completion of Sandfire’s Entitlement Offer, Metal Tiger will be interested in 6,180,168 Sandfire Shares representing approximately 1.39% of Sandfire’s enlarged issue share capital.
Mosman Oil and Gas Ltd (AIM:MSMN) 0.0675p £4.3m
The oil exploration, development, and production company, provides an update in respect to the Cinnabar-1 well in Tyler County, Texas. The Cinnabar well was drilled in October 2022 and is now in the process of being completed and placed on production. Mosman confirms that the service rig is now on site and has started work on completing the well. Initial production flow rates are anticipated to be announced in 7-10 days.
Northcoders Group PLC (AIM:CODE) 310p £23.8m
The independent provider of training programmes for software coding, announces that its Business Solutions division has been awarded a new contract for £0.45m with R² Factory, part of Rolls Royce Group to run a developer incubator programme. This new contract follows on from a similar programme that Northcoders ran successfully for R² Factory last year which has just finished. During the last twelve months, Northcoders has secured multiple contracts such as with KPMG and EMaC Ltd.
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF)* 6.65p £33.3m
The infectious disease focused biopharmaceutical company, announces that it has acquired an exclusive licence from InsuCaps Limited (InsuCaps), a sister company of AnaBio Technologies (AnaBio), to use InsuCaps' patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome. Poolbeg will commence a proof-of-technology clinical trial in H1 2023 to determine that a Glucagon-like Peptide 1 receptor (GLP-1) agonist can be safely delivered orally in humans. GLP-1 agonists, which are used to treat diabetes and obesity, represent an extremely large, fast-growing opportunity estimated to grow to c.USD22bn p.a. by 2025. This exclusive licence is in addition to Poolbeg's exclusive license to AnaBio's microencapsulation and nanoencapsulation technologies which underpins Poolbeg's Oral Vaccine Platform. As previously announced, a Poolbeg-led consortium was been awarded Euro 2.3m in non-dilutive funding by the Irish Government's Disruptive Technologies Innovation Fund to progress the Oral Vaccine Platform.
Chef:
Emily Liu, CFA, CAIA
0203 764 2344
emily.liu@hybridan.com
Chef:
Sacha Morris
sacha.morris@hybridan.com
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.